ClinicalTrials.gg
RecruitingNCT07623369Updated Aug 21, 2026

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of HH160 in Solid Tumor, Non-small Cell Lung Cancer and Hepatocellular Carcinoma, sponsored by Huahui Health. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Huahui Health · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
299
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia — 123 open to participants now, 214 under way, 83 of them phase 3. Carcinoma, Non-Small-Cell Lung · Australia.

Planned enrollment
229th of 486
299 · median 271
Started
2026
with 30 others
Phase 1
115 of 499
28 open now
Primary completion
2027-08
later than 90 of 213 live
Registered
487th of 499
by date

Among the 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia, this one is the 229th largest by planned enrollment of the 486 interventional ones that give a count, is one of 31 that started in 2026, is one of 115 in phase 1, reaches primary completion later than 90 of the 213 other live ones, and was the 487th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

123 of the 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia are open now. Recruiting first, the newest first:

117 more — sign in →

All 123 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia, or all of them as a file.
02

Study summary

This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.

Read the detailed description

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary antitumor activity of HH160 alone or in combination with antitumor agents in participants with advanced or solid tumors, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastroesophageal adenocarcinoma (GEA), head and neck squamous cell carcinoma, renal cell carcinoma (RCC), endometrial carcinoma, cervical cancer, ovarian cancer, small cell lung cancer, triple-negative breast cancer, urothelial carcinoma, and additional tumor types based on emerging clinical data.

The study will also identify the recommended phase 1 dose (RP2D) of HH160 monotherapy and/or in combination with other chemotherapy regimens.

03

Conditions studied

  • Solid Tumor
  • Non-small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Renal Cell Carcinoma
  • Endometrial Cancer
  • Cervical Cancer
  • Small-cell Lung Cancer
  • Triple Negative Breast Cancer
  • Urothelial Carcinoma
  • Gastroesophageal Adenocarcinoma

Keywords

  • HH160
  • PD-1×CTLA-4×VEGF-A Antibody
  • Non-small Cell Lung Cancer
  • NSCLC
  • Hepatocellular Carcinoma
  • HCC
  • Colorectal Cancer
  • CRC
  • GEA
  • Head and Neck Squamous Cell Carcinoma
  • Renal Cell Carcinoma
  • RCC
  • Endometrial Cancer
  • Cervical Cancer
  • Small-cell Lung Cancer
  • Triple Negative Breast Cancer
  • TNBC
  • Urothelial Carcinoma
  • Gastroesophageal Adenocarcinoma
  • Ovarian Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Adults aged 18 to 75 years with signed .
  2. or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements.
  3. At least 1 per v1.1.
  4. Performance Status (ECOG) Performance Status of 0 or 1 with ≥ 12 weeks.
  5. Adequate organ function based on protocol-specified laboratory criteria.

Key Exclusion Criteria

  1. Active or uncontrolled/untreated .
  2. History of severe reactions to monoclonal antibodies, bispecific antibodies, trispecific antibodies, or study drug components.
  3. Other within 3 years prior to first dose, except specified curatively treated cancers.
  4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  5. Significant bleeding risk, severe coagulopathy, gastrointestinal hemorrhage, or recent pulmonary hemorrhage/hemoptysis.

NOTE: Other eligibility criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
299 participants (estimated)

Study arms

  • Experimental
    Phase 1a Part 1 : Dose Escalation

    Participants with advanced solid tumors will receive escalating doses of HH160

    Drug: HH160

  • Experimental
    Phase 1a Part 2: Safety Expansion

    Participants with selected advanced or metastatic solid tumors will receive HH160 at dose levels determined to be tolerable during dose escalation to further evaluate safety and tolerability.

    Drug: HH160

  • Experimental
    Phase 1b: Dose Expansion

    Additional participants with selected advanced or metastatic solid tumors will receive HH160 alone or in combination with chemotherapy at selected expansion dose levels and schedules identified during phase 1a.

    Drug: HH160

Interventions

  • DrugHH160

    Administered by intravenous infusion on Day 1 of each 21-day (Q3W) cycle or 14-day (Q2W) cycle.

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Assessed by treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events meeting protocol-defined dose-limiting toxicity (DLT) criteria.

    Time frame: From first dose of study drug to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first; up to approximately 12 months

  2. Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of HH160

    The MTD or MAD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 28%, or the highest dose administered, respectively.

    Time frame: From first dose through the end of Cycle 1 (approximately 1 month)

  3. Phase 1b: Recommended Phase 2 Dose (RP2D) of HH160

    RP2D is defined as the dose level selected based on the overall assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy

    Time frame: From first dose through completion of Phase 1b dose optimization (up to 2 years)

  4. Phase 1b: Overall Response Rate (ORR)

    Defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) assessed by the investigator.

    Time frame: Up to 2 years

Secondary outcomes

  1. Phase 1a: Objective Response Rate (ORR)

    Defined as the percentage of participants who achieved complete response (CR) or partial response (PR) as determined by investigator assessment using RECIST v1.1.

    Time frame: Up to 2 years

  2. Disease Control Rate (DCR)

    Defined as the percentage of participants who achieve a best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by investigator assessment using RECIST v1.1.

    Time frame: Up to 2 years

  3. Duration of Response (DOR)

    Defined as the time from the date that a response (CR or PR) was first observed to the date of first documented disease progression or death, whichever occurred first as determined by investigator assessment using RECIST v1.1.

    Time frame: Up to 2 years

  4. Progression-free Survival (PFS)

    PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first as determined by investigator assessment using RECIST v1.1.

    Time frame: Up to 2 years

  5. Phase 1a: Time to Response (TTR)

    TTR is defined as the time from start of treatment to the first date that response criteria (CR or PR) were met, as determined by investigator assessment using RECIST v1.1.

    Time frame: Up to 2 years

  6. Maximum Observed Plasma Concentration (Cmax) of HH160

    Time frame: Up to 4 months

  7. Elimination Half Time (T1/2) of HH160

    Time frame: Up to 4 months

  8. Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Up to 4 months

  9. Observed Clearance of HH160

    Time frame: Up to 4 months

  10. Area Under the Curve From Time Zero to Last Measurable Concentration (AUClast)

    Time frame: Up to 4 months

  11. Phase 1b: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Assessed by treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and AEs meeting protocol-defined adverse event of clinical interests (AECIs)..

    Time frame: From first dose of study drug to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first; up to approximately 2 years

07

Study locations

3 of 3 sites recruiting
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
    Recruiting
  • Tasman Health Care
    Southport, Queensland 4215, Australia
    Recruiting
  • Shandong Tumour Hospital Dongyuan Unit
    Jinan, Shandong, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 14 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 3, 2026
StartActual
Jun 11, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623369
Lead sponsor
Huahui Health
Collaborators
BeOne Medicines
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jun 11, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 21, 2026

Study contacts

Medical Officer
Contact
zhouxin@hhhbio.com
+86-010-80766688
Study Director
Contact
clinicaltrials@beonemed.com
1-877-828-5568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion